Ionis Pharma & Metagenomi announce research collab to leverage Ionis' RNA-targeted drugs expertise & Metagenomi's next-generation gene editing system (Moderna, BMS & Leaps by Bayer are investors). Ionis paid $80M upfront. Both expanding manufacturing in CA.endpts.com/ionis-partners…

Did you know that the world’s largest bacteria, Thiomargarita magnifica, was discovered in a mangrove and is about 5000x bigger than most other bacteria? That’s one mighty bacteria! #Metagenomi #Metagenomics

Don’t Forget - Metagenomi is hosting 1x1 meetings around the J.P. Morgan 41st Annual Healthcare Conference in San Francisco, January 9-11, 2023. Please email [email protected] to enquire about meeting availability

Happy Thanksgiving! Today (and every day), we are tremendously thankful for our team of bright, dedicated employees who all play a part in bringing our novel gene-editing technologies to the patients who need them the most. #Metagenomi #Biotech

Metagenomi’s Chief Investment Officer, Simon Harnest, will be presenting at the 34th Annual Piper Sandler Healthcare conference this week. #Metagenomi #Biotech

Simon Harnest, CIO at Metagenomi, will be speaking at the Evercore ISI HealthCONxConference. #Metagenomi

Our team took to the streets of Emeryville to enjoy a scenic social bike ride around the Bay Area. Come ride with us- join our team! Open positions below: metagenomi.co/careers/

Metagenomi President and COO, Jian Irish, has been awarded Endpoints News' Women in Biopharma award. This award highlights 20 female leaders who are making waves in R&D. Congrats to all recipients! endpts.com/special-report…

Today we published new data in Nature Communications describing novel, compact RNA-guided nucleases used to develop the smallest adenine base editor to date. Read here: nature.com/articles/s4146…

And last paper of the year I'll be tweeting about: The team at Metagenomi identifies and characterizes compact Cas9d and HEARO enzymes from uncultivated microbes go.nature.com/3vfuXFH

Metagenomi CEO and Founder, Brian C. Thomas, will discuss the future of the gene editing landscape with John Carroll, Founder & Editor of Endpoints News, during a fireside chat at #JPM23. Join us 1/9 from 11:35am - 12:00 pm PT for this robust discussion. jpm23.endpts.com

From our team to yours, we wish you a safe and joyful holiday season. As we wind down for our annual winter break and reflect on all of our accomplishments over this past year, we look forward to what’s to come in the new year.

As we begin a new year, we wanted to take a moment and reflect on what we accomplished in 2022. Here are just a few highlights! We can't wait to continue our work on novel gene editing technologies in 2023 and get one step closer to treating patients in need.

Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9th at the J.P. Morgan 41st Annual Healthcare Conference. ow.ly/8B1H50MiLoP

Today, we are proud to introduce the next evolution of the Metagenomi brand. Our logo is a celebration of the double helix, an homage to our discovery process and powerful engineering capabilities, as well as the upward, forward trajectory of our company. metagenomi.co